Bringing the Oncology Community Together

Dr. Sung Choi on Vorinostat in GVHD Prevention

Sung W. Choi, MD
Published Online: Friday, December 14, 2012
Sung W. Choi, MD, Assistant Professor, University of Michigan, discusses the results of a phase I/II trial examining the use of the histone deacetylase (HDAC) inhibitor vorinostat in graft-versus-host disease (GVHD) prevention.

Bone marrow transplantation is a potentially curative therapy for many hematological cancers as well as non-malignant conditions. GVHD remains a barrier to successful transplantation, Choi says, yet prevention therapies have not made much progress in the past 20 to 30 years.

The trial used a standard conditioning background of fludarabine and busulfan along with standard GVHD prophylaxis (tacrolimus and mycophenolate mofetil) then added the investigational agent, vorinostat. The combination was taken for 111 days before, during, and after bone marrow transplant.

The primary endpoint was the cumulative incidence of grade 2-4 acute GVHD with a target risk of 25% by day 100. The endpoint was reached: the cumulative incidence of day 100 grade 2-4 acute GVHD was 21% in the study group compared to 48% in the control, according to Choi. Further, transplant-related mortality was reduced and overall survival saw improvement in the study arm.

Related Articles
FDA Approves First-Line Ofatumumab for Fludarabine-Ineligble Patients With CLL
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Defining and Predicting Response to HMAs in MDS
In this segment, panelists discuss the lack of a clear connection between response to hypomethylating agents and molecular genetics as well as the larger role for cytogenetic assessment of response for patients with myelodysplastic syndrome.
Hypomethylating Agents in the Treatment of High-Risk MDS
In this section, panelists discuss the intricacies of administering hypomethylating agents for the treatment of patients with high-risk myelodysplastic syndrome.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.